Cancer Education
focusing on Specialized Topics of Interest

Taught by the Experts




www.BMLI.com
Overview Faculty & Disclsoure Agenda Colorado Convention Center Registration
Live Simulcast Educational Needs Target Audience Learning Objectives CME/CE Credit Information
Click here to Register: Live Symposium or Live Simulcast
Great Debates in Lung Cancer:Integrating the New Paradigm of Immuno-Oncology into Non-Small Cell Lung Cancer Management
1:45PM Registration and Lunch
2:45PM Welcome and CME/CE Pre Test
Karen Kelly, MD
2:50PM
And Now for Something Completely Different - A New Era of Immuno-Oncology for NSCLC
H. Jack West, MD
3:05PM
Debate #1: Should Immuno-Oncology therapy be administered broadly or selectively to NSCLC patients?
  • Immuno-Oncology therapy is a new standard of care for chemotherapy-pretreated patients with advanced NSCLC.
    Hossein Borghaei, DO
  • Immuno-Oncology therapy should be used selectively, based on clinical and/or biomarker variables.
    Edward Garon, MD
3:15PM Expert Panel Discussion and Audience Q & A
Joan Schiller, MD
3:25PM
Debate #2: Are there clinically meaningful differences among immune checkpoint inhibitors?
  • The various immune checkpoint inhibitors have clinically meaningful differences in efficacy and toxicity profiles when used to for patients with NSCLC.
    H. Jack West, MD
  • There are no significant functional differences among the immune checkpoint inhibitors that are either FDA approved or in late-stage clinical testing in lung cancer.
    Charles Rudin, MD, PhD
3:35PM Expert Panel Discussion and Audience Q & A
Charles Rudin, MD, PhD
3:45PM
Debate #3: Differences in Toxicities and Toxicity Prevention and Management Strategies Between Conventional Systemic Therapy and Immuno-Oncology Therapy: Are any differences sufficiently significant to select Immuno-Oncology Therapy versus Conventional Therapy in some patients?
  • Immuno-oncology provides an opportunity for lower therapy-induced toxicity risk.
    Karen Kelly, MD
  • Toxicity Issues with Immuno-Oncology are a significant challenge versus conventional chemotherapy and targeted therapy.
    Joan Schiller, MD
3:55PM Expert Panel Discussion and Audience Q & A
Karen Kelly, MD
4:10PM Closing Remarks and CME/CE Test
H. Jack West, MD
4:15PM Adjourn
Overview Back to top
Co-Chairs: Drs. Jack West & Karen Kelly

The primary objective is to provide the target audience of oncologists, hematologist/oncologists, and other clinicians with knowledge and competence involving immuno-oncology that helps them implement practice performance changes so that they can improve outcome in their NSCLC patients. The symposium addresses the key, clinical and scientific issues facing oncologists and other healthcare professionals treating NSCLC patients with Immuno-Oncology.

The agenda is comprised of a very lively and interactive learning format. The participants in the audience will be interacting with the 6 expert faculty members throughout the program. Using their own iPads, iPhones, laptops or any Wi-Fi-enabled smart devices to connect to the symposium network, the audience will answer treatment and patient care questions, vote to show who they believe won each of the 3 debates, and, ask questions of the faculty at any time. These audience questions will be constantly queued-up and addressed by the faculty in each of the three Expert Panel Discussion sessions.

To begin the symposium Dr. Karen Kelly will welcome everyone, introduce the 6 expert lung cancer faculty members and ask four CME/CE test questions to assess the baseline knowledge of the audience regarding Immuno-Oncology for NSCLC.

Dr. Jack West will continue the program with his presentation, "And now for something completely different - A new era of Immuno-Oncology for NSCLC." Dr. West will review his topic with a quasi-didactic presentation that involves asking the audience numerous clinical care questions throughout his 15 minute session to keep the audience engaged while they learn about the important clinical and scientific differences between Immuno-Oncology and traditional systemic therapy for NSCLC.

The symposium continues with three debates on key, practical, patient care questions involving the integration of Immuno-Oncology into the new paradigm for NSCLC management. 1) Should Immuno-Oncology therapy be administered broadly or selectively to NSCLC patients?   2) Are there clinically meaningful differences among immune checkpoint inhibitors? and, 3) Are any differences sufficiently significant to cause a clinician to select either Immuno-Oncology Therapy or Conventional Therapy for some NSCLC patients?  The audience is engaged with these three debates by voting before and after each of the 6 debaters.

Following each of the three debates is a 10-minute Expert Panel Discussion where the 6 experts discuss the debate topic further, and also answer the questions that have been queued-up by the audience using their iPads or other smart devises throughout the symposium.  This ability to ask questions with this iPad and queued-up format has become one of the most popular items on the already highly interactive agenda.

The symposium concludes with re-asking the CME/CE test questions to determine how successful the symposium was to impart knowledge and competence.  Comparisons of the pre and post symposium answers by the audience will be briefly reviewed to conclude the program.

To receive CME/CE credit the learners have up to one week to complete the required symposium survey and answer 4 knowledge test questions found on the BioMedical Learning Institute (BMLI) Website. All of the PowerPoint slides, recorded audio and the presentations will be available in approximately 6 weeks following the symposium.

Bring your own Smartphones, Tablets, or Laptops
(iPad, Android, iPhone, etc.): This will enable participants to use their personal "smart devices" during the symposium to ask and answer all questions of the faculty.

This activity is being hosted in association with
Faculty Disclosure Information Back to top
Howard "Jack" West, MD (Co-Chair & Course Director)
Medical Oncologist
Thoracic Oncology Specialist
Swedish Medical Center
President & CEO of GRACE
Global Resource for Advancing Cancer Education
Seattle, WA

Consulting Fees: AstraZeneca, BMS, Genentech/Roche
Fees for Non-CME/CE Services Received Directly from Commercial Interest or Their Agents (e.g. speakers’ bureaus): AstraZeneca
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

Hossein Borghaei, DO
Chief, Thoracic Oncology
Director, Lung Cancer Risk Assessment
Fox Chase Comprehensive Cancer Center
Philadelphia, PA

Consulting Fees: BMS, Celgene, Lilly, Clovis and Genentech
Honoraria: BMS, Celgene
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

Edward B. Garon, MD
Associate Clinical Professor
Department of Medicine
Director, Thoracic Oncology Program
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, CA

Contracted Research: BMS, Merck, Novartis, Pfizer, AstraZeneca, Genentech, Heat
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

Karen Kelly, MD (Co-Chair & Course Director)
Professor of Medicine
Associate Director for Clinical Research
Endowed Chair in Cancer Clinical Research
UC Davis Comprehensive Cancer Center
Sacramento, CA

I have no real or apparent conflicts of interest to report.

Charles Rudin, MD, PhD
Medical Oncologist
Chief, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
Co-Chair Eastern Cooperative Oncology Group
Member, National Cancer Institute
Thoracic Malignancies Steering Committee

Consulting Fees: Celgene, GSK, Boehringer Ingelheim. Merck, Clovis

Joan Schiller, MD
Professor of Medicine
Chief, Division of Hematology-Oncology
University of Texas Southwestern Medical Center
Deputy Director,
Simmons Comprehensive Cancer Center
Dallas, TX

Consulting Fees: Genentech/Roche


LEAD NURSE PLANNER
Diane D. DePew, DSN, RN-BC

I have no real or apparent conflicts of interest to report.

PLANNER & CME/CE REVIEWER
Stephen Madison, BsPharm, RPh, MBA, CHCP (BMLI Manager)

I have no real or apparent conflicts of interest to report.

CME/CE PEER REVIEWER
Danielle Shafer, MD

I have no real or apparent conflicts of interest to report.

Supported by an Educational Grant from Bristol-Myers Squibb
Educational Needs Back to top

Lung cancer is a significant unmet medical need. It is the leading cause of cancer deaths in the US and in many other countries. In 2014, according to the American Cancer Society Facts and Figures there were an estimated 224,210 new cases, and 159,260 deaths from lung cancer. Survival rates vary depending upon the stage of the lung malignancy when it is diagnosed. Globally, the five-year survival rate for Stage I NSCLC is approximately 50 percent. For Stage IV NSCLC, the five-year survival rate is approximately two percent. Thus, it is clear that a significant unmet medical need exists for patients with lung cancer.

Because Immuno-Oncology is so different from traditional systemic therapy for lung cancer, targeted therapy and chemotherapy, a significant educational need exists to help medical oncologists and other healthcare professionals (HCPs) quickly understand how to utilize immunotherapy in their practices to help improve their lung cancer patients’ outcomes today.

Target Audience Back to top

The target audience for this symposium on Immuno-Oncology for NSCLC includes medical oncologists, hematologists, radiation oncologists, surgical oncologists, pathologists, Fellows, Physician Assistants, oncology nurses/Nurse Practitioners, oncology pharmacists, and other allied health-care professionals involved in the treatment, care and management of patients with NSCLC. Lung cancer is treated optimally by a multi-disciplinary approach and, thus, all of the aforementioned clinician specialties are invited to participate in this symposium.

The BioMedical Learning Institute (BMLI) maintains three separate accreditations: ACCME, ANCC and ACPE, to provide CME for physicians, CNE for nurses and CPE for pharmacists. Other clinical specialties can also earn credit as described below.

  • Physicians can earn CME credit: 1.5 AMA PRA Category 1 Credits™.
  • Nurses and Nurse Practitioners can earn CNE credit: 1.5 contact hours
  • Pharmacists can earn CPE credit: 1.5 contact hours or .15 CEUs
  • Physician Assistants can use Certificates of Attendance from BMLI for 1.5 hours Category 1 Credit from AOACCME
  • Fellows can use Certificates of Attendance from BMLI for 1.5 hours Credit

Learning Objectives Back to top

Based on the data identified in the Practice Gap Identification and Analysis of this Needs Assessment, the following Learning Objectives have been developed for these CME/CE activities. Separate learning objectives have been developed for physicians, nurses and pharmacists because their roles in addressing unmet medical needs of patients with squamous NSCLC are significantly different.

PHYSICIANS
  1. Analyze the differences in how efficacy is measured when NSCLC treatment is immuno-oncology therapy versus traditional chemotherapy or targeted therapy.
  2. Compare and contrast the differences in Mechanisms of Action between immune therapy and traditional targeted and chemotherapy for NSCLC.
  3. Critically assess the recent data using immune-therapy versus chemotherapy plus targeted therapy for second-line therapy of NSCLC.
  4. Evaluate the strategies for determining which NSCLC patients are candidates to receive immuno-oncology therapy versus treatment with traditional targeted or chemotherapy.
NURSES
  1. List the differences in how efficacy is measured when NSCLC treatment is immuno-oncology therapy versus traditional chemotherapy or targeted therapy.
  2. Recall the differences in Mechanisms of Action between immune therapy and traditional targeted and chemotherapy for NSCLC.
  3. Critically assess the recent data using immune-therapy versus chemotherapy plus targeted therapy for second-line therapy of NSCLC.
  4. Describe the strategies for determining which NSCLC patients are candidates to receive immuno-oncology therapy versus treatment with traditional targeted or chemotherapy.
PHARMACISTS
  1. List the differences in how efficacy is measured when NSCLC treatment is immuno-oncology therapy versus traditional chemotherapy or targeted therapy.
  2. Recall the differences in Mechanisms of Action between immune therapy and traditional targeted and chemotherapy for NSCLC.
  3. Critically assess the recent data using immune-therapy versus chemotherapy plus targeted therapy for second-line therapy of NSCLC.
  4. Describe the strategies for determining which NSCLC patients are candidates to receive immuno-oncology therapy versus treatment with traditional targeted or chemotherapy.
CME/CE Credit Information Back to top

Physicians

The BioMedical Learning Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The BioMedical Learning Institute designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists

The BioMedical Learning Institute is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: 0838-0000-15-005-L01-P
Credits: 1.5 hours (0.15 ceus)
Type of Activity: Knowledge

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Nurses

The BioMedical Learning Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The BioMedical Learning Institute designates this educational activity for 1.5 contact hours.

Accreditation by the American Nurses Credentialing Center's Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Other

Physician Assistants: AAPA accepts certificates of attendance for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 1.5 hours of Category 1 credit for attending this symposium.

Fellows will receive a certificate of attendance that they can submit to their accrediting organizations for continuing education credit.

Colorado Convention Center Back to top

Colorado Convention Center
Rooms: Mile High 2 + 3
700 14th St
Denver, CO 80202
Phone: (303) 228-8000

Live Internet Simulcast Back to top

Options for your participation in the Internet Simulcast
You have 2 ways to participate in this symposium via the Internet Simulcast. Either way will enable you to CME/CE credit.

  • Interactive: One involves interactive participation enabling you ask questions of the faculty just like the participants in the live meeting in Chicago, and to interact with the program and answer clinical and case study questions during each presentation.
  • Non-Interactive: The other way to participate is to watch and listen to the symposium without the ability to ask or answer questions.

If you choose interactive participation for the symposium you will need to have 2 separate internet browser windows open. One browser window is to view and hear the symposium presentations, and the other is to ask and answer questions during the symposium. Each browser window connects to a different Web Site.

You can do this any of a number of ways including having 2 browser windows open on one large computer screen or use your iPhone or iPad or other smart device as your second browser window to answer and ask questions and your computer browser window to view and listen to the symposium.

To connect to view and listen to the symposium in a non-interactive manner please click on the following Web Site hyperlink: http://www.liveeventstream.com/bmli/bmli_09062015.html

To connect to the second Web Site which enables you to ask and answer questions please click on the following Web Site hyperlink with your other browser window or iPad, iPhone, etc.: https://bmli.cnf.io

Technical Requirements and Testing Your Connections  

It is highly recommended you test your connection(s) between 1:45PM to 2:45PM Mountain Time. Our system will be operational during this 60 minute time period which has been dedicated for testing and if you have any questions during this time please use the support chat feature (link to right Web Site) or call the following telephone number: 1-800-209-1868

Minimum Requirements for the Live Internet Simulcast
PC Requirements

You need Windows XP Service Pack 2, Windows Vista, Windows 7 or Windows 8, and you'll need to use Internet Explorer or Firefox for your web browser. You should have at least a 1.2-gigahertz processor and 512 megabytes of RAM. Your Internet connection speed should be at least 1.5 Mbps.

Mac Requirements

You need an Intel-based computer with at least OS 10.4.11 and Firefox 3 or Safari 3. You'll also need at least 1 gigabyte of RAM. Your Internet connection speed should be at least 1.5 Mbps. The Microsoft Silverlight plug-in will be required (it is generally installed on most computers already). You can check here if you have it installed: https://www.microsoft.com/getsilverlight/Get-Started/Install/Default.aspx

Faculty Disclosures of Conflicts of Interest

The attached document contains a list of faculty, BMLI staff members, and other healthcare professionals who have reported real or apparent conflicts of interest (COIs).  According to the ACCME, ACPE and ANCC, COIs are any "relevant financial relationships with commercial supporters" of this symposium.  For your information, all of the conflicts of interest have all been resolved through a rigorous ACCME, ACPE and ANCC-approved peer-review process prior to the symposium.  Please review this faculty disclosure COI document carefully prior to your participation in this symposium.

Symposium Sessions

The scientific sessions of the symposium on Sunday, September 6, 2015 are scheduled from at 2:45 p.m. to 4:15 p.m mountain time.  The agenda is contained in the enclosed attachment.

Slides, Presentations and Other Archived Materials Slides, all presentations and other archived materials (all panel discussions and Q & A sessions) from this symposium will be posted on the www.BMLI.com Web site in approximately 6 weeks.

CME, CE Certificates, Certificates of Attendance and Completed Symposium Evaluation Forms
You will receive your CME or CE Certificate, or Certificate of Attendance approximately 4 to 6 weeks following the symposium. To receive any of these certificates, participants are required by the ACCME and ACPE to complete the Evaluation Form and then to submit the completed Evaluation Form using your iPad or smart device. To receive CE contact hour credit attendance at the entire activity and the successful completion of the post-test and evaluation form is required. By completing the Evaluation Form, participants are documenting their attendance and claiming their number of CME/CE credit hours. Fellows may complete a Certificate of Attendance for use in seeking CE credit in their States.

This presentation was approved by the 16th World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the 16th World Conference on Lung Cancer. This presentation is not sponsored or endorsed by IASLC.